These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 10451780)

  • 1. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Li RC; Zhu M; Schentag JJ
    Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pharmacodynamic parameters for antimicrobial agents.
    Li RC
    Int J Antimicrob Agents; 2000 Feb; 13(4):229-35. PubMed ID: 10755236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
    Dudley MN; Ambrose PG
    Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
    Pickerill KE; Paladino JA; Schentag JJ
    Pharmacotherapy; 2000 Apr; 20(4):417-28. PubMed ID: 10772373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of fluoroquinolones.
    Lode H; Borner K; Koeppe P
    Clin Infect Dis; 1998 Jul; 27(1):33-9. PubMed ID: 9675446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Wispelwey B
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S127-35. PubMed ID: 15942879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of fluoroquinolone pharmacodynamics.
    Wright DH; Brown GH; Peterson ML; Rotschafer JC
    J Antimicrob Chemother; 2000 Nov; 46(5):669-83. PubMed ID: 11062185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.
    Perry TR; Schentag JJ
    Clin Pharmacokinet; 2001; 40(9):685-94. PubMed ID: 11605716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices.
    Barbour A; Scaglione F; Derendorf H
    Int J Antimicrob Agents; 2010 May; 35(5):431-8. PubMed ID: 20219329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.
    Maglio D; Nicolau DP
    Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs.
    Papich MG
    Vet Microbiol; 2014 Jul; 171(3-4):480-6. PubMed ID: 24513278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.